0 231

Cited 1 times in

Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author한광협-
dc.date.accessioned2017-11-02T08:22:44Z-
dc.date.available2017-11-02T08:22:44Z-
dc.date.issued2017-
dc.identifier.issn1936-0533-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154399-
dc.description.abstractBACKGROUND: There is no approved therapy for patients with failed transarterial chemoembolization (TACE) and progression of hepatocellular carcinoma. We aimed to investigate the efficacy and prognostic factors in patients with TACE failure who received sorafenib rescue therapy. METHODS: We investigated 54 patients who met the criteria of TACE failure as defined by the international guidelines of Europe and Japan. Sorafenib was used as a rescue therapy. Overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier methods, and multivariate analysis was performed to find prognostic factors. RESULTS: The patients were followed for a median 5.5 months, and the median duration of sorafenib administration was 3.3 months. The presence of main (or lobar) portal vein invasion (PVI) (3.7 versus 8.4 months, p = 0.004), dose reduction of sorafenib (4.0 versus 8.8 months, p = 0.002) and Child-Pugh class B (5.3 versus 8.9 months, p = 0.004) were associated with shorter OS compared to the presence of segmental PVI (or absence of macroscopic vascular invasion, MVI), full dosage of sorafenib and Child-Pugh class A, respectively. The presence of main (or lobar) PVI was associated with poorer PFS compared to the presence of segmental PVI (or absence of MVI) (2.1 versus 3.8 months p = 0.010). CONCLUSIONS: Sorafenib is a potential rescue therapy in patients with TACE failure. However, the clinical benefits need to be further evaluated for patients with main (or lobar) PVI or those treated with reduced doses of sorafenib.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer-
dc.relation.isPartOfHEPATOLOGY INTERNATIONAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHCarcinoma, Hepatocellular/drug therapy*-
dc.subject.MESHCarcinoma, Hepatocellular/pathology-
dc.subject.MESHChemoembolization, Therapeutic/methods-
dc.subject.MESHDisease Progression-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms/drug therapy*-
dc.subject.MESHLiver Neoplasms/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Invasiveness-
dc.subject.MESHNiacinamide/administration & dosage-
dc.subject.MESHNiacinamide/adverse effects-
dc.subject.MESHNiacinamide/analogs & derivatives*-
dc.subject.MESHNiacinamide/pharmacology-
dc.subject.MESHPhenylurea Compounds/administration & dosage-
dc.subject.MESHPhenylurea Compounds/adverse effects-
dc.subject.MESHPhenylurea Compounds/pharmacology*-
dc.subject.MESHPortal Vein/pathology*-
dc.subject.MESHPrognosis-
dc.subject.MESHProtein Kinase Inhibitors/therapeutic use-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTreatment Failure-
dc.subject.MESHTreatment Outcome-
dc.titlePrognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorSangheun Lee-
dc.contributor.googleauthorJung Hyun Kang-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorKwang-Hyub Han-
dc.identifier.doi10.1007/s12072-017-9792-3-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA04268-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ00986-
dc.identifier.eissn1936-0541-
dc.identifier.pmid28324324-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs12072-017-9792-3-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordOverall survival-
dc.subject.keywordPrognosis-
dc.subject.keywordSorafenib-
dc.subject.keywordTransarterial chemoembolization-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Beom Kyung-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.citation.titleHepatology International-
dc.citation.volume11-
dc.citation.number3-
dc.citation.startPage292-
dc.citation.endPage299-
dc.identifier.bibliographicCitationHEPATOLOGY INTERNATIONAL, Vol.11(3) : 292-299, 2017-
dc.date.modified2017-11-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.